Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222572 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01222572 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 1 participants.
The verdict
NCT01222572, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely. Because stereotactic radiation is so precise, the investigators are testing whether it can be used to increase the dose to the primary tumor without significantly increasing the side effects the participant experiences; the goal is to improve the likelihood of killing the tumor.
Interventions
- DRUG Cisplatin
- DRUG Etoposide
- RADIATION Stereotactic boost
- RADIATION Conventional RT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01222572
The ClinicalTrials.gov registry entry for NCT01222572 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT01222572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01222572 about?
NCT01222572 is a clinical study titled "Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer". In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely. Because stereotactic radiation is so precise, the investigators are testing whether it can be used to increase the dose to the primary tumor without significantly inc...
What is the current status of trial NCT01222572?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2010-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01222572?
The interventions under investigation include: Cisplatin (DRUG), Etoposide (DRUG), Stereotactic boost (RADIATION), Conventional RT (RADIATION).
Who is sponsoring clinical trial NCT01222572?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.